Transverse Myelitis Market Research Report – Forecast to 2027

Global Transverse Myelitis Research Report: By Diagnosis (Magnetic Resonance Imaging (MRI), Lumbar Puncture, Blood Tests, Others), by Treatment (Intravenous Steroids, Plasma Exchange Therapy, Antiviral Medication, Others), by End-User– Forecast Till 2027

ID: MRFR/MED/5028-HCR | | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Global transverse myelitis market is expected to grow at a steady pace over the forecast period. It is projected to grow at a CAGR of 3.2% over the assessment period. Transverse myelitis is a neurological disease caused by inflammation of both sides of one section of the spinal cord. This condition generally damages the insulating material covering the nerve cell fibers (myelin). Transverse myelitis can occur at any age. According to the Columbia University Department of Neurology, this disease most often occurs in children ages 10 to 19 years and in adults aged 30 to 39 years. The inflammation leading to transverse myelitis can result as a side effect of a number of other conditions such as measles, viral infections, lyme disease, syphilis, viral infections, and bacterial infections among others. The common symptoms of the disease include back or neck pain, weakness in arms or legs, abnormal sensations in the legs, loss of bowel control and sensory symptoms such as numbness.


The factors such as growing prevalence of transverse myelitis, rising prevalence of diseases which can lead to transverse myelitis such as viral infections and some cancers, increasing in research and development activities, and rising expenditure on healthcare sector by the government in developed as well as developing economies is expected to fuel the global transverse myelitis market. According to the National Multiple Sclerosis Society, it is estimated that about 1,400 new cases of transverse myelitis are diagnosed each year in the US. According to the same source, it is estimated that about 33,000 American population have some type of disability resulting from transverse myelitis.


Despite the drivers, high cost associated with the diagnosis and treatment of transverse myelitis can hamper the growth of the market over the assessment period.


Segmentation


The global transverse myelitis market has been segmented into diagnosis, treatment, end user, and region.


The market, by diagnosis, has been segmented into magnetic resonance imaging (MRI), lumbar puncture, blood tests, and others.


The market, by treatment, has been segmented into intravenous steroids, plasma exchange therapy, antiviral medication, pain medications, physical therapy, occupational therapy, psychotherapy, and others. The pain medication has been further segmented into chronic pain medication and nerve pain medication. The chronic pain segment has been further segmented into acetaminophen, ibuprofen, and naproxen sodium. The nerve pain medication has been segmented into sertraline, gabapentin, and pregabalin.


On the basis of end user, the market has been segmented into hospitals & clinics, diagnostic centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The transverse myelitis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European transverse myelitis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The transverse myelitis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The transverse myelitis market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Medtronic, Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Baxter International, Inc., Amgen Inc., Johnson & Johnson Consumer Inc., Bayer AG, Pfizer, Inc., Cerus Corporation, Haemonetics Corporation, GlaxoSmithKline, and Bristol-Myers-Squibb are some key players in the market.


Regional Market Summary


Global Transverse Myelitis Market Share (%), by Region, 2017


Transverse Myelitis Market Share


Source: Centers for Disease Control and Prevention (CDC), White Papers, Company Presentations


Geographically, the Americas is anticipated to dominate the global transverse myelitis market owing to a well-developed healthcare sector, rising prevalence of transverse myelitis, and a relatively large number of research and development activities. According to the Centers for Disease Control and Prevention (CDC), total national expenditure was USD for 3.3 trillion in 2016.


Europe is expected to hold the second largest position in the global transverse myelitis market. The market growth in this region is attributed to the rising incidence of transverse myelitis and rising government expenditure for the healthcare sector. According to the Transverse Myelitis Society, transverse myelitis has an incidence of 300 new cases per year in the UK.


The transverse myelitis market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, growing awareness about rare diseases, and increasing government funding for the healthcare sector.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector, increasing occurrence of transverse myelitis and growing government initiatives for the healthcare sector. According to an article published in the NCBI in May 2018, the adult prevalence rate for Emirati citizens was 2.46 per 100,000 citizens for monophasic transverse myelitis.


Global Transverse Myelitis Market, by Diagnosis



  • Magnetic Resonance Imaging (MRI)

  • Lumbar Puncture

  • Blood Tests

  • Others


Global Transverse Myelitis Market, by Treatment



  • Intravenous Steroids

  • Plasma exchange Therapy

  • Antiviral Medication

  • Pain Medications

  • Chronic Pain

  • Acetaminophen

  • Ibuprofen

  • naproxen sodium

  • Nerve Pain

  • sertraline

  • gabapentin

  • pregabalin

  • Physical Therapy

  • Occupational Therapy

  • Psychotherapy

  • Others


Global Transverse Myelitis Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Others


Global Transverse Myelitis Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • The Middle East & Africa



  • Middle East

  • Africa


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities



Frequently Asked Questions (FAQ) :


Transverse Myelitis Market CAGR would be 3.2% during the forecast period.

The restraints would be the high cost of diagnosis and treatment for Transverse Myelitis Market.

The treatment types in the Transverse Myelitis Market are antiviral medication, intravenous steroids, plasma exchange therapy, physical therapy, pain medications, psychotherapy, occupational therapy, and others.

The end users are diagnostic centers, hospitals & clinics, and others.

The Americas would lead the Transverse Myelitis Market.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Transverse Myelitis Market, by Diagnosis

6.1 Introduction

6.2 Magnetic Resonance Imaging (MRI)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Lumbar Puncture

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Blood Tests

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Others

Chapter 7. Global Transverse Myelitis Market, by Treatment

7.1 Introduction

7.2 Intravenous Steroids

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Plasma Exchange Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Antiviral Medication

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Pain Medication

7.5.1 Chronic Pain Medication

7.5.1.1 Acetaminophen

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5.1.2 Ibuprofen

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5.1.3 Naproxen Sodium

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5.2 Nerve Pain Medication

7.5.2.1 Sertraline

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5.2.2 Gabapentin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5.2.3 Pregabalin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Physical Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7 Occupational Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.8 Psychotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.9 Others

Chapter 8. Global Transverse Myelitis Market, by End-User

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Others

Chapter 9. Global Transverse Myelitis Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Medtronic, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 B. Braun Melsungen AG

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Fresenius Kabi AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Baxter International, Inc.

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Amgen, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Johnson & Johnson Consumer Inc.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Bayer AG

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Pfizer, Inc.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Cerus Corporation

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Haemonetics Corporation

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 GlaxoSmithKline

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Bristol-Myers-Squibb

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Transverse Myelitis Industry

Chapter 13. Appendix

LIST OF TABLES

Table 1 Global Transverse Myelitis Market Synopsis, 2020-2027

Table 2 Global Transverse Myelitis Market Estimates and Forecast, 2020-2027

(USD Million)

Table 3 Global Transverse Myelitis Market, by Region, 2020-2027 (USD Million)

Table 4 Global Transverse Myelitis Market, by Diagnosis, 2020-2027 (USD Million)

Table 5 Global Transverse Myelitis Market, by Treatment, 2020-2027 (USD Million)

Table 6 Global Transverse Myelitis Market, by End-User, 2020-2027 (USD Million)

Table 7 North America: Transverse Myelitis Market, by Diagnosis, 2020-2027 (USD

Million)

Table 8 North America: Transverse Myelitis Market, by Treatment, 2020-2027 (USD

Million)

Table 9 North America: Transverse Myelitis Market, by End-User, 2020-2027 (USD

Million)

Table 10 US: Transverse Myelitis Market, by Diagnosis, 2020-2027 (USD Million)

Table 11 US: Transverse Myelitis Market, by Treatment, 2020-2027 (USD Million)

Table 12 US: Transverse Myelitis Market, by End-User, 2020-2027 (USD Million)

Table 13 Canada: Transverse Myelitis Market, by Diagnosis, 2020-2027 (USD Million)

Table 14 Canada: Transverse Myelitis Market, by Treatment, 2020-2027 (USD Million)

Table 15 Canada: Transverse Myelitis Market, by End-User, 2020-2027 (USD

Million)

Table 16 South America: Transverse Myelitis Market, by Diagnosis, 2020-2027 (USD

Million)

Table 17 South America: Transverse Myelitis Market, by Treatment, 2020-2027 (USD

Million)

Table 18 South America: Transverse Myelitis Market, by End-User, 2020-2027 (USD

Million)

Table 19 Europe: Transverse Myelitis Market, by Diagnosis, 2020-2027 (USD Million)

Table 20 Europe: Transverse Myelitis Market, by Treatment, 2020-2027 (USD Million)

Table 21 Europe: Transverse Myelitis Market, by End-User, 2020-2027 (USD Million)

Table 22 Western Europe: Transverse Myelitis Market, by Diagnosis, 2020-2027

(USD Million)

Table 23 Western Europe: Transverse Myelitis Market, by Treatment, 2020-2027

(USD Million)

Table 24 Western Europe: Transverse Myelitis Market, by End-User, 2020-2027

(USD Million)

Table 25 Eastern Europe: Transverse Myelitis Market, by Diagnosis, 2020-2027

(USD Million)

Table 26 Eastern Europe: Transverse Myelitis Market, by Treatment, 2020-2027

(USD Million)

Table 27 Eastern Europe: Transverse Myelitis Market, by End-User, 2020-2027

(USD Million)

Table 28 Asia-Pacific: Transverse Myelitis Market, by Diagnosis, 2020-2027 (USD

Million)

Table 29 Asia-Pacific: Transverse Myelitis Market, by Treatment, 2020-2027 (USD

Million)

Table 30 Asia-Pacific: Transverse Myelitis Market, by End-User, 2020-2027 (USD

Million)

Table 31 Middle East & Africa: Transverse Myelitis Market, by Diagnosis, 2020-2027

(USD Million)

Table 32 Middle East & Africa: Transverse Myelitis Market, by Treatment, 2020-2027

(USD Million)

Table 33 Middle East & Africa: Transverse Myelitis Market, by End-User, 2020-2027

(USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Transverse Myelitis Market

Figure 3 Segmentation Market Dynamics for Global Transverse Myelitis Market

Figure 4 Global Transverse Myelitis Market Share, by Diagnosis, 2020

Figure 5 Global Transverse Myelitis Market Share, by Treatment, 2020

Figure 6 Global Transverse Myelitis Market Share, by End-User, 2020

Figure 7 Global Transverse Myelitis Market Share, by Region, 2020

Figure 8 North America: Transverse Myelitis Market Share, by Country, 2020

Figure 9 Europe: Transverse Myelitis Market Share, by Country, 2020

Figure 10 Asia-Pacific: Transverse Myelitis Market Share, by Country, 2020

Figure 11 Middle East & Africa: Transverse Myelitis Market Share, by Country, 2020

Figure 12 Global Transverse Myelitis Market: Company Share Analysis, 2020 (%)

Figure 13 Medtronic, Inc.: Key Financials

Figure 14 Medtronic, Inc.: Segmental Revenue

Figure 15 Medtronic, Inc.: Geographical Revenue

Figure 16 B. Braun Melsungen AG: Key Financials

Figure 17 B. Braun Melsungen AG: Segmental Revenue

Figure 18 B. Braun Melsungen AG: Geographical Revenue

Figure 19 Fresenius Kabi AG: Key Financials

Figure 20 Fresenius Kabi AG: Segmental Revenue

Figure 21 Fresenius Kabi AG: Geographical Revenue

Figure 22 Baxter International, Inc. : Key Financials

Figure 23 Baxter International, Inc.: Segmental Revenue

Figure 24 Baxter International, Inc.: Geographical Revenue

Figure 25 Amgen, Inc.: Key Financials

Figure 26 Amgen, Inc.: Segmental Revenue

Figure 27 Amgen, Inc.. Geographical Revenue

Figure 28 Johnson & Johnson Consumer Inc.: Key Financials

Figure 29 Johnson & Johnson Consumer Inc.: Segmental Revenue

Figure 30 Johnson & Johnson Consumer Inc.: Geographical Revenue

Figure 31 Bayer AG: Key Financials

Figure 32 Bayer AG: Segmental Revenue

Figure 33 Bayer AG: Geographical Revenue

Figure 34 Pfizer, Inc.: Key Financials

Figure 35 Pfizer, Inc.: Segmental Revenue

Figure 36 Pfizer, Inc.: Geographical Revenue

Figure 37 Cerus Corporation: Key Financials

Figure 38 Cerus Corporation: Segmental Revenue

Figure 39 Cerus Corporation: Geographical Revenue

Figure 40 Haemonetics Corporation: Key Financials

Figure 41 Haemonetics Corporation: Segmental Revenue

Figure 42 Haemonetics Corporation: Geographical Revenue

Figure 43 GlaxoSmithKline: Key Financials

Figure 44 GlaxoSmithKline: Segmental Revenue

Figure 45 GlaxoSmithKline: Geographical Revenue

Figure 46 Bristol-Myers-Squibb: Key Financials

Figure 47 Bristol-Myers-Squibb: Segmental Revenue

Figure 48 Bristol-Myers-Squibb: Geographical Revenue